AstraZeneca Q3 Profit Jumps 23% to $3.1B on Cancer Drug Strength

British pharma giant AstraZeneca reports 23% net profit surge to $3.12 billion for Q3 2026 (July-September), driven by cancer treatments that now make up 48% of its $16.2 billion quarterly revenue. CEO Pascal Soriot highlights 180+ pipeline projects and a new $1.5 billion annual savings programme (costing $2 billion to implement) to fund further drug development.

The company stays on track for its 2030 target of $80 billion annual revenue—up from $59 billion in 2023—with the US expected to deliver half that goal. AstraZeneca began direct NYSE listing in February to attract American investors and pledged $15 billion China investment by 2030 for manufacturing and research expansion. Beyond oncology, the firm is developing a weight-loss treatment to compete with GLP-1 blockbusters like Wegovy and Mounjaro.

Share price rose 3.1% on the London Stock Exchange following the announcement. Net profit for the first nine months of 2026 stands at $8.7 billion.

For Nigerian investors tracking global pharma or healthcare equities, this signals continued oncology dominance and strategic US/China pivot. The weight-loss pipeline entry could reshape metabolic drug markets globally. Are you positioned for pharma's shift toward specialty medicines and emerging market manufacturing?

SOURCE: https://www.channelstv.com/2026/10/30/drugs-giant-astrazeneca-reveals-higher-profits-savings-plan/